Angiogenesis--a new goal in peripheral artery occlusive disease therapy.
The vasculature is mostly quiescent in the normal adult, with the exception of the growth of new blood vessels during the female reproductive cycle. Recent advances in the knowledge concerning the molecular changes and the identification of genetic events in this vascular quiescence, as well as in vascular growth, has led to an increasing number of studies in which these phenomena are manipulated. Angiogenesis is the growth of new vessels from existing ones. Although new vessel formation is involved in many pathologic situations, like tumour growth, therapeutic angiogenesis has been presented as a novel method for the treatment of ischemic diseases, like peripheral arterial occlusive disease (PAOD). In experimental studies therapeutic angiogenesis has been produced by recombinant growth-factor protein application as well as by growth factor gene therapy. Most widely studied factors belong to vascular endothelial growth factor (VEGF) or fibroblast growth factor (FGF) families. Studies have also shown that, angiogenic growth factors stimulate endothelial cell migration and accelerate endothelial repair by enhancing post-injury re-endothelization. In clinical studies angiogenic therapy has been evaluated in patients with severe vascular diseases. The results have revealed that therapy is well tolerated as well as safe and that angiogenic therapy has a clear biologic effect. However, controlled studies are still needed to answer the question whether therapeutic angiogenesis offers a real clinical benefit to patients with PAOD.
Mäkinen
K
K
Kuopio University Hospital, 70211 Kuopio, Finland. kimmo.makinen@kuh.fi
D000328:Adult; D043924:Angiogenesis Modulating Agents / Q000494:pharmacology*; D001157:Arterial Occlusive Diseases / Q000188:drug therapy*; D005069:Evaluation Studies as Topic; D005346:Fibroblast Growth Factors / Q000494:pharmacology; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D018919:Neovascularization, Physiologic / Q000187:drug effects / Q000235:genetics* / Q000502:physiology*; D016491:Peripheral Vascular Diseases / Q000188:drug therapy*; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000494:pharmacology
D043924:Angiogenesis Modulating Agents; D042461:Vascular Endothelial Growth Factor A; D005346:Fibroblast Growth Factors